Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cerebral hypoxia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11 result(s) found for: Cerebral hypoxia. Displaying page 1 of 1.
    EudraCT Number: 2012-001049-42 Sponsor Protocol Number: Start Date*: 2012-07-05
    Sponsor Name:Department of Oncology, Rigshospitalet
    Full Title: MRI-perfusion and FLT- and FET-PET during bevacizumab monotherapy for patients with recurrent Glioblastoma Multiforme
    Medical condition: Recurrent Glioblastoma multiforme
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-000509-58 Sponsor Protocol Number: RC31/18/0472 Start Date*: 2019-10-08
    Sponsor Name:CHU de Toulouse
    Full Title: Cerebral hemodynamic optimization by milrinone for the prevention of delayed cerebral ischemia in severe subarachnoid hemorrhages
    Medical condition: delayed cerebral ischemia in severe subarachnoid hemorrhages
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004852 10019587 Hemorrhage subarachnoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-015852-11 Sponsor Protocol Number: TC-FMISO-PET-06-1413 Start Date*: 2012-02-03
    Sponsor Name:Hospital Universitario Dr. Negrin
    Full Title: 18F-FMISO-PET in High Grade Gliomas: Assessment of Tumor Hypoxia and Effect of Spinal Cord Stimulation
    Medical condition: Hypoxia in malignant brain tumors: high grade gliomas
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-014344-11 Sponsor Protocol Number: prot-001-2009 Start Date*: 2010-06-02
    Sponsor Name:Imperial College London
    Full Title: Neuroprotective effects of hypothermia combined with inhaled xenon following perinatal asphyxia - the TOBY Xe trial
    Medical condition: Neonatal asphyxial encephalopathy
    Disease: Version SOC Term Classification Code Term Level
    12 10028946 neonatal hypoxia and asphyxia SOC
    Population Age: Newborns, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-003238-35 Sponsor Protocol Number: 4_141221 Start Date*: 2021-09-15
    Sponsor Name:Oslo University Hospital
    Full Title: Effects of supplemental oxygen on systemic and cerebral hemodynamics in experimental hypovolemia: A randomized, phase IV, crossover study to study the effect of supplemental oxygen vs. room air on ...
    Medical condition: Hypovolemia is the condition under investigation. Hypovolemia is induced by the "lower body negative pressure" (LBNP)-model.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10049771 Shock haemorrhagic PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: View results
    EudraCT Number: 2015-003063-12 Sponsor Protocol Number: NEU-01-02-1A Start Date*: 2016-09-14
    Sponsor Name:Neurophyxia B.V.
    Full Title: TIBC study: A multiple-centre Phase 2 trial comparing the efficacy of 2-Iminobiotin (2-IB) treatment to standard care in neonates with gestational age of ≥36 weeks with moderate to severe perinatal...
    Medical condition: Perinatal asphyxia
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003500 Asphyxia neonatal LLT
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10028923 Neonatal asphyxia PT
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10004943 Birth asphyxia LLT
    19.0 100000004868 10028946 Neonatal hypoxia and asphyxia HLT
    19.0 100000004852 10021147 Hypoxic encephalopathy LLT
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10022820 Intrauterine hypoxia and birth asphyxia LLT
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10040441 Severe birth asphyxia LLT
    19.0 100000004852 10070512 Hypoxic-ischemic encephalopathy LLT
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2020-003601-66 Sponsor Protocol Number: CSEG101ANL01T Start Date*: 2021-07-14
    Sponsor Name:Amsterdam UMC - AMC
    Full Title: The Effect of Crizanlizumab on Cerebral Perfusion and Oxygenation in Sickle Cell Patients
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003138-18 Sponsor Protocol Number: UCC-Strider Start Date*: Information not available in EudraCT
    Sponsor Name:University College Cork
    Full Title: STRIDER Ireland: A Randomised Controlled Trial of Sildenafil Therapy In Dismal Prognosis Early‐Onset Intrauterine Growth Restriction
    Medical condition: Severe early - onset Intrauterine Growth Restriction (IUGR), (also referred to as Fetal growth restriction) diagnosed between 22+0 and 29+6 gestational age. IUGR is defined as an estimated fetal we...
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004868 10070532 Fetal growth restriction LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-000702-19 Sponsor Protocol Number: LITE Start Date*: 2015-07-22
    Sponsor Name:Rigshospitalet
    Full Title: Haemostatic and Fibrinolytic Analysis of Low Molecular Weight Heparin Injections versus Unfractionated Heparin Infusion as Post-CABG Thromboprophylaxis
    Medical condition: Deep venous thrombosis, myocardial infarction, cerebral infarction, bleeding
    Disease: Version SOC Term Classification Code Term Level
    19.0 10042613 - Surgical and medical procedures 10062354 Ischaemic heart disease prophylaxis PT
    19.0 100000004849 10023024 Ischaemic heart disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003406-14 Sponsor Protocol Number: UHNM1219 Start Date*: 2017-09-26
    Sponsor Name:University Hospital of North Midlands NHS Trust
    Full Title: The Metoclopramoide and selective oral decontamination for Avoiding Pneumonia after Stroke (MAPS-2) Trial: a 2x2 double-blind, randomized controlled trial of metoclopramide and selective oral decon...
    Medical condition: Stroke We are testing two differnt intervetnions which could prevent pneumonia in stroke patietns. Prevention pneumonia could potentiallly speed up recovery and improve survival.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10035669 Pneumonia aspiration PT
    20.0 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    20.1 10029205 - Nervous system disorders 10019016 Haemorrhagic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001834-25 Sponsor Protocol Number: MasterDapt Start Date*: 2017-11-07
    Sponsor Name:ECRI-9
    Full Title: MAnagement of high bleeding risk patients post bioresorbable polymer coated STEnt implantation with an abbReviated versus prolonged DAPT regimen – MASTER DAPT
    Medical condition: High bleeding risk population represents a significant proportion of coronary artery disease (CAD) patients undergoing coronary stent implantation. Decisions regarding the duration of dual antiplat...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007541 Cardiac disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) ES (Completed) SE (Completed) DE (Completed) IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 01:10:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA